Literature DB >> 30561688

Relative Effectiveness of Cell-Cultured and Egg-Based Influenza Vaccines Among Elderly Persons in the United States, 2017-2018.

Hector S Izurieta1,2, Yoganand Chillarige3, Jeffrey Kelman4, Yuqin Wei3, Yun Lu1, Wenjie Xu3, Michael Lu3, Douglas Pratt1, Steve Chu4, Michael Wernecke3, Thomas MaCurdy3, Richard Forshee1.   

Abstract

BACKGROUND: The low influenza vaccine effectiveness (VE) observed during the A(H3N2)-dominated 2017-2018 season may be due to vaccine virus adaptation to growth in eggs. We compared the effectiveness of cell-cultured and egg-based vaccines among Medicare beneficiaries.
METHODS: Retrospective cohort study on Medicare beneficiaries aged ≥65 years who received an influenza vaccine (cell-cultured, egg-based quadrivalent; egg-based high-dose, adjuvanted, or standard-dose trivalent) during the 2017-2018 season. We used Poisson regression to evaluate relative VE (RVE) in preventing influenza-related hospital encounters.
RESULTS: Of >13 million beneficiaries, RVE for cell-cultured vaccines relative to egg-based quadrivalent vaccines was 10% (95% confidence interval [CI], 7%-13%). In a midseason interim analysis, this estimate was 16.5% (95% CI, 10.3%-22.2%). In a 5-way comparison, cell-cultured (RVE, 11%; 95% CI, 8%-14%) and egg-based high-dose (RVE, 9%; 95% CI, 7%-11%) vaccines were more effective than egg-based quadrivalent vaccines.
CONCLUSIONS: The modest VE difference between cell-cultured and egg-based vaccines only partially explains the low overall VE reported by the Centers for Disease Control and Prevention, suggesting that egg adaptation was not the main contributor to the low VE found among individuals aged ≥65 years. The midseason interim analysis we performed demonstrates that our methods can be used to evaluate VE actively during the influenza season.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cell-cultured vaccine; influenza vaccine; relative vaccine effectiveness; vaccine effectiveness

Mesh:

Substances:

Year:  2019        PMID: 30561688     DOI: 10.1093/infdis/jiy716

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  54 in total

1.  Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence.

Authors:  Ilaria Loperto; Andrea Simonetti; Antonio Nardone; Maria Triassi
Journal:  Hum Vaccin Immunother       Date:  2019-03-25       Impact factor: 3.452

2.  Challenges in estimating influenza vaccine effectiveness.

Authors:  Kylie E C Ainslie; Michael Haber; Walt A Orenstein
Journal:  Expert Rev Vaccines       Date:  2019-05-31       Impact factor: 5.217

3.  Reply to letter from Alvarez et al.

Authors:  Jesús Ruiz-Aragón; Ray Gani; Sergio Márquez; Piedad Alvarez
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

4.  Atti del 52° Congresso Nazionale: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI).

Authors: 
Journal:  J Prev Med Hyg       Date:  2019-10-15

5.  Projected Population Benefit of Increased Effectiveness and Coverage of Influenza Vaccination on Influenza Burden in the United States.

Authors:  Michelle M Hughes; Carrie Reed; Brendan Flannery; Shikha Garg; James A Singleton; Alicia M Fry; Melissa A Rolfes
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

6.  Quadrivalent cell culture influenza virus vaccine. Comparison to egg-derived vaccine.

Authors:  Alberto Pérez-Rubio; Julio Ancochea; Jose María Eiros Bouza
Journal:  Hum Vaccin Immunother       Date:  2020-04-07       Impact factor: 3.452

Review 7.  Challenges of Making Effective Influenza Vaccines.

Authors:  Sigrid Gouma; Elizabeth M Anderson; Scott E Hensley
Journal:  Annu Rev Virol       Date:  2020-05-11       Impact factor: 10.431

8.  Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines During the 2017-2018 Season.

Authors:  Sigrid Gouma; Seth J Zost; Kaela Parkhouse; Angela Branche; David J Topham; Sarah Cobey; Scott E Hensley
Journal:  Clin Infect Dis       Date:  2020-09-12       Impact factor: 9.079

9.  Summary of the NACI Supplemental Statement on Mammalian Cell Culture-Based Influenza Vaccines.

Authors:  Angela Sinilaite; Ian Gemmill; Robyn Harrison
Journal:  Can Commun Dis Rep       Date:  2020-10-01

10.  Relative and Absolute Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults-United States, 2015-2017.

Authors:  Joshua D Doyle; Lauren Beacham; Emily T Martin; H Keipp Talbot; Arnold Monto; Manjusha Gaglani; Donald B Middleton; Fernanda P Silveira; Richard K Zimmerman; Elif Alyanak; Emily R Smith; Brendan L Flannery; Melissa Rolfes; Jill M Ferdinands
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.